Novocure Posts Record Revenue on Global Patient Growth
Event summary
- Q2 2026 revenue hit $183.6M, up 16% YoY, driven by active patient growth.
- Optune Gio saw 11% global patient increase; Optune Lua grew 51%.
- $4.9M tariff refund boosted gross margin to 78% from 74% YoY.
- Adjusted EBITDA turned positive at $10.8M, up from $(9.9)M last year.
- Full-year revenue guidance raised to $710M-$725M from prior $690M-$710M.
The big picture
Novocure's Q2 results highlight the scalability of its TTFields therapy model across aggressive cancer indications. The company's ability to maintain double-digit patient growth while improving profitability signals operational maturity in a competitive oncology landscape. Strategic expansion into pancreatic and lung cancer markets positions Novocure for continued revenue diversification.
What we're watching
- Regulatory Milestones
- FDA decision on brain metastases indication and KEYNOTE D58 trial completion in Q4 2026 will shape growth trajectory.
- Market Expansion
- Optune Pax's CE Mark approval for pancreatic cancer opens new European revenue streams.
- Operational Efficiency
- Sustainability of mid-70s gross margins depends on avoiding one-time benefits like tariff refunds.
Related topics